Edition:
United Kingdom

Luye Pharma Group Ltd (2186.HK)

2186.HK on Hong Kong Stock

8.21HKD
20 Apr 2018
Change (% chg)

HK$-0.18 (-2.15%)
Prev Close
HK$8.39
Open
HK$8.36
Day's High
HK$8.50
Day's Low
HK$8.13
Volume
22,449,900
Avg. Vol
26,690,892
52-wk High
HK$9.75
52-wk Low
HK$3.95

Select another date:

Tue, Apr 10 2018

BRIEF-Luye Pharma Group Says LY03003 Drug Approved To Proceed To Phase III Clinical Trials In China

* LY03003 OBTAINED APPROVAL FROM CHINA FOOD AND DRUG ADMINISTRATION TO PROCEED TO PHASE III CLINICAL TRIALS IN CHINA Source text for Eikon: Further company coverage:

BRIEF-Luye Pharma Group Posts FY Profit Attributable Of RMB981.4 Million​

* ‍FY PROFIT ATTRIBUTABLE ROSE 10.1% TO RMB981.4 MILLION​ Source text for Eikon: Further company coverage:

BRIEF-Luye Pharma Group Announces collaboration With Excel Biopharma

* Immuno-Oncology Antibody Drug Development Collaboration With Excel Biopharm

BRIEF-Luye Pharma Group Says ‍Rotigotine Exempted From Phase 2 Dosage Exploration Clinical Trials​

* ‍ROTIGOTINE EXTENDED RELEASE MICROSPHERES FOR INJECTION IS EXEMPTED FROM PHASE II DOSAGE EXPLORATION CLINICAL TRIALS​ Source text for Eikon: Further company coverage:

BRIEF-Luye Pharma Group Says ‍CFDA Accepted Clinical Trial Application For Co's Anti-Tumor Drug

* ‍CFDA OFFICIALLY ACCEPTED CLINICAL TRIAL APPLICATION FOR ANTI-TUMOR DRUG Source text for Eikon: Further company coverage:

BRIEF-Luye Pharma Group Says FDA To Waive Pediatric Clinical Trials Of Schizophrenia Drug

* FDA AGREES TO WAIVE PEDIATRIC CLINICAL TRIALS OF SCHIZOPHRENIA DRUG LY03004

BRIEF-Luye Pharma Group's Drug Approved By U.S. FDA

* ‍GROUP'S DRUG ROTIGOTINE EXTENDED RELEASE MICROSPHERES FOR INJECTION HAS BEEN APPROVED BY U.S. FDA

BRIEF-Luye Pharma ‍Updates On Development Of Ansofaxine Hydrochloride Extended Release Tablets​

* ‍UPDATES ON PHASE II CLINICAL TRIAL IN CHINA FOR ANSOFAXINE HYDROCHLORIDE EXTENDED RELEASE TABLETS​

BRIEF-Luye Pharma Group‍ Announces Update on Patent Litigation Regarding Rivastigmine 1 Day Patch

* COURT OF APPEAL FOR DISTRICT OF MUNICH, GERMANY DISMISSES APPEAL FROM NOVARTIS AG AS CLAIMANT IN PATENT INFRINGEMENT LAWSUIT

BRIEF-Luye Pharma Says ‍Unit Applies To Register For Proposed Issue Of Debt Securities

* ‍UNIT APPLIES TO NATIONAL ASSOCIATION OF FINANCIAL MARKET INSTITUTIONAL INVESTORS TO REGISTER FOR PROPOSED ISSUE OF DEBT SECURITIES

Select another date: